Drug Profile
Research programme: recombinant glucosylceramidase - JCR Pharmaceuticals/GlaxoSmithKline
Alternative Names: JR-101Latest Information Update: 28 Feb 2023
Price :
$50
*
At a glance
- Originator JCR Pharmaceuticals
- Developer GlaxoSmithKline KK; JCR Pharmaceuticals
- Class Enzymes; Recombinant proteins
- Mechanism of Action Glucosylceramidase replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Gaucher's disease
Most Recent Events
- 28 Feb 2023 Discontinued - Preclinical for Gaucher's disease in Japan (unspecified route) (JCR Pharmaceuticals pipeline, February 2023)
- 28 Aug 2018 No recent reports of development identified for preclinical development in Gaucher's-disease in Japan
- 12 Aug 2016 Preclinical development is ongoing for Gaucher's disease in Japan (JCR Pharmaceuticals pipeline, August 2016)